-- The national disease awareness campaign aims
to educate and drive conversation about recognizing and managing
non-motor symptoms of Parkinson’s, including hallucinations and
delusions
-- Reynolds and his mother Tammy share their
personal story about the impact of these symptoms on their
family
Ryan Reynolds, a world-renowned actor/entrepreneur and
Parkinson’s disease advocate, with Acadia Pharmaceuticals Inc.
(Nasdaq: ACAD) today announced the launch of a multi-faceted
disease education campaign, More to Parkinson’s®, to raise
awareness among caregivers, patients and their care providers about
a common, yet under-recognized aspect of Parkinson’s disease –
Parkinson’s-related hallucinations and delusions.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240801386480/en/
Ryan & Tammy Reynolds (Photo:
Business Wire)
Notably, around half of the people living with Parkinson’s
disease may develop hallucinations or delusions over the course of
their disease, but up to 90% of people currently do not proactively
tell their physicians about these symptoms.1-3 By sharing their
experiences caring for Ryan’s father, James “Jim” Reynolds, who
passed away nearly a decade ago, Ryan and his mother Tammy, aim to
raise awareness, educate and drive conversation between people with
Parkinson’s disease, their families and their doctors about how
best to talk about and treat these non-motor symptoms.
“My father experienced hallucinations and delusions. At the
time, we didn’t know any of these types of symptoms were part of
his Parkinson’s disease,” Reynolds explains. “Like a lot of
caregivers, my mom mostly tried to carry these burdens alone. I
wish I’d known Parkinson’s disease wasn’t limited to only motor
symptoms. I think people and families affected by Parkinson’s can
be better prepared to manage hallucinations and delusions if
they’re talking early and often about this lesser-known aspect of
the disease.”
This press release features multimedia. View the full release
here: https://www.businesswire.com/news/home/54103329/en.
“In my experience, most people living with Parkinson’s disease
who experience hallucinations and delusions do not proactively tell
their physicians about them unless specifically asked,” explains
Dr. Yasar Torres-Yaghi, attending physician, director of
Parkinsonism and Dementia Clinic at Georgetown University Hospital,
Washington, D.C., a Parkinson’s Center of Excellence. “They may be
frightened, embarrassed, or fear they are losing touch with
reality. It’s important for people who are living with Parkinson’s
and their loved ones to discuss all symptoms, motor and non-motor,
with a doctor as there are treatment options available.”
More to Parkinson’s is an educational campaign, sponsored
by Acadia Pharmaceuticals Inc., that aims to increase awareness
among caregivers and patients of the existence of hallucinations
and delusions as common parts of Parkinson’s disease. The campaign
is anchored by a series of stories shared by Ryan and his mother,
Tammy, as they relay their personal experiences from the
perspective of a son and caregiver as well as a wife, mother, and
caregiver, over the course of Jim’s disease. The multichannel
campaign includes videos spanning a wide range of topics focusing
on Parkinson’s-related hallucinations and delusions, covering who
is at risk, what symptoms may look like, how to discuss symptoms
and treatment options with a doctor, and more. The campaign will
strive to reach the Parkinson’s disease community through digital
media, social media and connected TV.
“There is a significant gap in awareness and understanding that
hallucinations and delusions can be part of the progression of
Parkinson’s disease,” said Steve Davis, Chief Executive Officer,
Acadia. “As Ryan’s family story makes evident, the non-motor
symptoms of Parkinson’s, including hallucinations and delusions,
are often more distressing and disruptive than the motor symptoms
associated with the disease. We are honored that Ryan and Tammy are
willing to share their powerful story. Their experiences will open
the door to desperately needed conversation and encourage people to
speak with their healthcare providers about managing these
symptoms.”
To learn more, visit MoretoParkinsons.com to find resources,
including doctor and family discussion guides, and hear stories
from people who have been affected by Parkinson’s-related
hallucinations and delusions.
About Parkinson’s Disease and Parkinson’s-Related Hallucinations
and Delusions
Parkinson’s disease is a progressive nervous system disorder
that affects about one million people in the United States.4,5 The
signs and symptoms can vary with people experiencing both motor
symptoms and non-motor symptoms such as hallucinations (seeing,
hearing, or experiencing things that others don’t) and delusions
(false beliefs). Physicians may refer to these Parkinson’s-related
hallucinations and delusions as Parkinson’s disease psychosis.3,6,8
Around 50 percent of people living with Parkinson’s disease may
experience hallucinations or delusions during the course of their
disease.1 Non-motor symptoms, as a whole, can be more troublesome
than motor symptoms, in terms of quality of life.3 Parkinson’s
disease psychosis may add to the burden of caring for a loved one
with Parkinson’s disease.9-11
About Acadia Pharmaceuticals Inc.
Acadia is advancing breakthroughs in neuroscience to elevate
life. For 30 years we have been working at the forefront of
healthcare to bring vital solutions to people who need them most.
We developed and commercialized the treatment options for people
living with hallucinations and delusions associated with
Parkinson’s disease and Rett syndrome. Our clinical-stage
development efforts are focused on treating, Prader-Willi syndrome,
Alzheimer’s disease psychosis and multiple other programs targeting
neuropsychiatric symptoms in central nervous system disorders. For
more information, visit us at Acadia.com and follow us on LinkedIn
and Twitter.
References
1 Forsaa EB, Larsen JP, Wentzel-Larsen T, et al. A 12-year
population-based study of psychosis in Parkinson disease. Arch
Neurol. 2010;67(8):996-1001. 2 Fénelon G, Mahieux F, Huon R,
Ziégler M. Hallucinations in Parkinson’s disease: prevalence,
phenomenology and risk factors. Brain. 2000;123(Pt 4):733-745. 3
Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, et al. The
nondeclaration of nonmotor symptoms of Parkinson’s disease to
health care professionals: an international study using the
nonmotor symptoms questionnaire. Mov Disord. 2010;25(6):704-709. 4
Parkinson’s Foundation. What is Parkinson’s? Retrieved from
https://www.parkinson.org/Understanding-Parkinsons/Statistics.
Accessed March 1, 2024. 5 Marras C, Beck JC, Bower JH, et al.;
Parkinson’s Foundation P4 Group. Prevalence of Parkinson's disease
across North America. NPJ Parkinsons Dis. 2018 Jul 10;4:21. 6
Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for
psychosis in Parkinson’s disease: report of an NINDS, NIMH work
group. Mov Disord. 2007 Jun 15;22(8):1061-8. 7 Martinez-Martin P,
Schapira AHV, et al. Prevalence of Nonmotor Symptoms in Parkinson’s
Disease in an International Setting: Study using Nonmotor Symptoms
Questionnaire in 545 Patients. Mov Disord. 2007; 22(11): 1623-1629.
8 Olanow CW, Schapira AHV. 2012. Parkinson’s Disease and Other
Movement Disorders. Fauci AS (Ed), Harrison’s Principles of
Internal Medicine (18th ed.). 9 Martinez-Martin P,
Rodriguez-Blazquez C, et al. The Impact of Non-Motor Symptoms on
Health Related Quality of Life of Patients with Parkinson’s
Disease. Mov Disord. 2011;26(3):399-406. 10 Aarsland D, Bronnick K,
Ehrt U, et al. Neuropsychiatric symptoms in patients with
Parkinson’s disease and dementia: frequency, profile and associated
care giver stress. J Neurol Neurosurg Psychiatry. 2007;78:36-42. 11
Schrag A, Hovris A, et al. Caregiver-burden in parkinson’s disease
is closely associated with psychiatric symptoms, falls, and
disability. Parkinsonism and Related Disorders. 2006;12:35-41.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240801386480/en/
Investor Contact: Acadia Pharmaceuticals Inc. Al Kildani
(858) 261-2872 ir@acadia-pharm.com
Media Contact: Acadia Pharmaceuticals Inc. Deb Kazenelson
(818) 395-3043 media@acadia-pharm.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
過去 株価チャート
から 11 2024 まで 12 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
過去 株価チャート
から 12 2023 まで 12 2024